Literature DB >> 2814169

Dermatologic manifestations of Lyme disease.

B W Berger1.   

Abstract

Erythema migrams (EM), the distinctive cutaneous lesion of Lyme disease, has a variable clinical appearance, but at some point presents as a centrifugally expanding, usually erythematous, annular patch. Of 237 patients with this condition, 201 (85%) were examined initially from May through September. Thirty-four (14%) remembered having been bitten by a deer tick. The median interval from the bite to the appearance of EM was 9 days (range, 1-36 days). Forty-one (17%) of the patients had multiple EM lesions. Of the 237 patients, 128 (54%) manifested major extracutaneous signs and symptoms. Although EM also has a variable histologic picture, the presence of a deep and superficial perivascular and interstitial lymphohistiocytic infiltrate containing plasma cells is diagnostic. Spirochetes can be demonstrated with Warthin-Starry staining in approximately 40% of the biopsy specimens. Concomitant cutaneous lesions appeared on some patients before and during antibiotic therapy. Nine patients with serologic evidence of Borrelia burgdorferi infection had cutaneous lesions other than EM, including granuloma annulare (three), erythema nodosum (two), papular urticaria (two), Henoch-Schönlein-like purpura (one), and morphea (one). Whether these entities are cutaneous markers of Lyme disease or are coincidental findings is yet to be determined.

Entities:  

Mesh:

Year:  1989        PMID: 2814169     DOI: 10.1093/clinids/11.supplement_6.s1475

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  27 in total

Review 1.  Clinical manifestations of tick-borne infections in children.

Authors:  K A Bryant; G S Marshall
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  Laboratory confirmation of Lyme disease.

Authors:  T G Schwan; W J Simpson; P A Rosa
Journal:  Can J Infect Dis       Date:  1991

3.  Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14.

Authors:  G H Giambartolomei; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

5.  Serodiagnosis in early Lyme disease.

Authors:  M E Aguero-Rosenfeld; J Nowakowski; D F McKenna; C A Carbonaro; G P Wormser
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

Review 6.  Systematic review of the treatment of early Lyme disease.

Authors:  P S Loewen; C A Marra; F Marra
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

7.  CD14 mediates cross talk between mononuclear cells and fibroblasts for upregulation of matrix metalloproteinase 9 by Borrelia burgdorferi.

Authors:  Zhihui Zhao; Rhonda Fleming; Bilaal McCloud; Mark S Klempner
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

8.  Unusual features in the epidemiology of Lyme borreliosis.

Authors:  L Angelov
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

9.  Evaluation of RevA, a fibronectin-binding protein of Borrelia burgdorferi, as a potential vaccine candidate for lyme disease.

Authors:  Angela M Floden; Tammy Gonzalez; Robert A Gaultney; Catherine A Brissette
Journal:  Clin Vaccine Immunol       Date:  2013-04-17

10.  Dermal inflammation elicited by synthetic analogs of Treponema pallidum and Borrelia burgdorferi lipoproteins.

Authors:  M V Norgard; B S Riley; J A Richardson; J D Radolf
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.